In a Phase 2a clinical trial, Columbia researchers found that the drug AEFO117 significantly reduced the effects of cannabis in daily cannabis smokers.
A Columbia study finds that adolescents who use cannabis recreationally are two to four times as likely to develop psychiatric disorders then teens who don’t use cannabis at all.